lansoprazole has been researched along with Tuberculosis, Drug-Resistant in 2 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rybniker, J | 2 |
| Kohl, TA | 1 |
| Barilar, I | 1 |
| Niemann, S | 1 |
| Vocat, A | 1 |
| Sala, C | 1 |
| Busso, P | 1 |
| Pojer, F | 1 |
| Benjak, A | 1 |
| Cole, ST | 1 |
2 other studies available for lansoprazole and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
No Evidence for Acquired Mutations Associated with Cytochrome
Topics: Antitubercular Agents; Electron Transport Complex III; Humans; Lansoprazole; Microbial Sensitivity T | 2019 |
Lansoprazole is an antituberculous prodrug targeting cytochrome bc1.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antitubercular Agents; Cell Line; Drug Discovery; | 2015 |